Acetylon Pharmaceuticals Initiates New Phase 1b Clinical Trial of Rocilinostat (ACY-1215) in Combination with Celgene’s Revlimid® (Lenalidomide) and Dexamethasone for Patients with Multiple Myeloma
Other Sources for this Article
Acetylon Pharmaceuticals, Inc.
Walter C. Ogier, 617-245-1300
President and Chief Executive Officer
MacDougall Biomedical Communications
Kari Watson, 781-235-3060